TY - JOUR T1 - Treatment of life-threatening digoxin toxicity with digoxin-specific antibody fragments: results from a prospective, non-interventional observational UK patient registry study JF - European Journal of Hospital Pharmacy JO - Eur J Hosp Pharm DO - 10.1136/ejhpharm-2022-003416 SP - ejhpharm-2022-003416 AU - Emma Thomas AU - Sam Tomlinson AU - Siwan Thomas AU - Suzanne Ward AU - Claire Daugherty AU - Eva Gallardo AU - Christon Hill Y1 - 2022/10/21 UR - http://ejhp.bmj.com/content/early/2022/10/21/ejhpharm-2022-003416.abstract N2 - Digoxin is expected to remain a widely prescribed medication for atrial fibrillation and cardiovascular disorders generally. Digoxin toxicity can occur, and severe toxicity represents a medical emergency, with intravenous administration of digoxin-specific antibody fragments (DIF; DigiFab, Protherics Medicines Development Ltd) indicated in the presence of life-threatening arrhythmias.1 2In the prospective, non-interventional observational UK DigiFab Patient Registry study, carried out as a post-authorisation requirement from the Medicines and Healthcare Products Regulatory Agency, we evaluated real-world safety and efficacy of DIF for treating known or strongly suspected life-threatening digoxin toxicity. Physicians at UK hospitals were invited to submit registry forms for any patient receiving DIF according to indication (known or strongly suspected life-threatening digoxin toxicity associated with ventricular arrhythmias or bradyarrhythmias unresponsive to atropine, where measures beyond withdrawal of digoxin and correction of serum electrolytes are considered necessary).2 Assessment of completed forms and administration of the registry was managed by Protherics Medicines Development Ltd. Reports of adverse events (AEs), adverse drug reactions or lack of efficacy were followed up … ER -